AZEVAN PHARMACEUTICALS, INC.

BETHLEHEM, PA · Biotech · Private

Orally bioavailable vasopressin V1a receptor antagonists for CNS disorders

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · azevan.com

Sector: Biotech
Headquarters: BETHLEHEM, PA
Latest Form D: $2.2M, Oct 2013
Total capital: $5.9M

Federal grants: $3.7M; 2 awards · 2019–2020; Rank in peer group#260 of 514
Private capital raised: $2.2M; 1 Form D · last Oct 2013; 156 months since last filing
Federal contracts: None on recordNo federal contract awards found.
Granted patents: 6; 15 pending · first 2017; Rank in peer group#58 of 514

Capital timeline

Latest events

Sep 2020Federal grantHealth and Human S · Phase II · Advancing SRX246 to Commericialization$3.2M
May 2019Federal grantHealth and Human S · Phase I · A New Drug for the Treatment of Traumatic Brain Injury$501K
Oct 2013Private capital raisedForm D · SEC · 1st filing$2.2M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 514 peers

Line = median

Biotech · Molecule

Federal grantsBelow median
Granted patents#58 · top 11%
Linked publications#17 · top 3%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings

Carter G. MeyerDirectorNamed in SEC Form D filings
Geoffrey G. SmithDirectorNamed in SEC Form D filings
Mike G. PaviaDirectorNamed in SEC Form D filings
Morton G. HymanDirectorNamed in SEC Form D filings
Neal G. SimonExecutive Officer, DirectorNamed in SEC Form D filings
Paul J. MaddonDirectorNamed in SEC Form D filings

What it has protected

USPTO · 6 granted of 21

Apr 11, 2024PendingCompositions And Methods For Treating Brain InjuryUSPTOApplication 18135225
Apr 20, 2023PendingCompositions And Methods For Treating Neurodegenerative DiseasesUSPTOApplication 17732631
Apr 18, 2023GrantedCompositions And Methods For Treating Brain InjuryUSPTOUS 11,628,160

Show all 21 patent records

Compositions And Methods For Treating Brain InjuryApr 11, 2024 · Application 18135225Pending
Compositions And Methods For Treating Neurodegenerative DiseasesApr 20, 2023 · Application 17732631Pending
Compositions And Methods For Treating Brain InjuryApr 18, 2023 · US 11,628,160Granted
Compositions And Methods For Treating Neurodegenerative DiseasesMay 3, 2022 · US 11,319,306Granted
Methods For Treating Post Traumatic Stress DisorderMar 23, 2021 · US 10,953,001Granted
Compositions And Methods For Treating Neurodegenerative DiseasesJul 30, 2019 · US 10,364,236Granted
Methods For Treating Post Traumatic Stress DisorderJun 5, 2018 · US 9,987,265Granted
Compositions And Methods For Treating Neurodegenerative DiseasesOct 31, 2017 · US 9,802,925Granted
Compositions And Methods For Treating Brain InjuryApplication 62584343Pending
Compositions And Methods For Treating Brain InjuryApplication 62559113Pending
Compositions And Methods For Treating Brain InjuryApplication 62658758Pending
Compositions And Methods For Treating Brain InjuryApplication PCTUS2018051331Pending
Compositions And Methods For Treating Neurodegenerative DiseasesApplication PCTUS2015023060Pending
Compositions And Methods For Treating Neurodegenerative DiseasesApplication 61971862Pending
Methods For Treating Post Traumatic Stress DisorderApplication PCTUS2011042785Pending
Beta-lactam Cannabinoid Receptor ModulatorsApplication PCTUS2007078451Pending
B-lactamyl Vasopressin V2 AntagonistsApplication PCTUS2007064309Pending
Hydroxy And Keto-substituted Beta-lactamyl Alkanedioic AcidsApplication PCTUS2007006555Pending
Beta-lactamyl Phenylalanine, Cysteine, And Serine Vasopressin AntagonistApplication PCTUS2006027703Pending
Beta-lactamylalkanoic Acids For Treating Premenstrual DisordersApplication PCTUS2006010143Pending
Beta-lactamyl Vasopressin V1B AntagonistsApplication PCTUS2006010192Pending

Recent research by its founders

Vasopressin 1a Receptor Antagonists for Pathological Aggression in Neurodegenerative and Other CNS Diseases20260 cites
Endocrine and metabolic alterations in response to systemic inflammation and sepsis: a review article202544 cites
G protein coupled receptor transcripts in human immune cells and platelets20243 cites

PLUREXA LLCSimilar federal contract value in Biotech · null in contracts
CIRCCURE CORPORATIONSimilar federal contract value in Biotech · null in contracts
IMMUNOGENICS LLCSimilar federal contract value in Biotech · null in contracts
CARAVEL BIO, INC.Similar federal contract value in Biotech · null in contracts
Resilient Biotics, Inc.Similar federal contract value in Biotech · null in contracts
Model Medicines, Inc.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.